Efficacy and safety of ferric carboxymaltose and other formulations in iron-deficient patients: a systematic review and network meta-analysis of randomised controlled trials

Ferric carboxymaltose is a new intravenous iron formulation that allows the administration of high doses of iron over a limited time. Although it was proved to be effective and safe in different clinical studies, extensive use in iron-deficient patients was not supported by strong scientific evidence. The aim of this study was to conduct a systematic review and network meta-analysis of randomised controlled trials to combine the highest quality (direct and indirect) evidence regarding the efficacy and safety of ferric carboxymaltose compared with other available iron formulations. Ferric carboxymaltose seems to provide a better and more rapid correction of haemoglobin and serum ferritin levels in iron-deficient patients compared to other iron formulations.